Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/RALBP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/RALBP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/RALBP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/RALBP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/RALBP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/RALBP1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/RALBP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/RALBP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00482855 | Thyroid | PTC | organelle fission | 188/5968 | 488/18723 | 9.64e-04 | 5.77e-03 | 188 |
GO:004354714 | Thyroid | PTC | positive regulation of GTPase activity | 103/5968 | 255/18723 | 2.38e-03 | 1.25e-02 | 103 |
GO:00350239 | Thyroid | PTC | regulation of Rho protein signal transduction | 40/5968 | 86/18723 | 3.15e-03 | 1.54e-02 | 40 |
GO:0098754110 | Thyroid | PTC | detoxification | 63/5968 | 152/18723 | 7.92e-03 | 3.34e-02 | 63 |
GO:00901402 | Thyroid | PTC | regulation of mitochondrial fission | 17/5968 | 32/18723 | 1.02e-02 | 4.11e-02 | 17 |
GO:000726524 | Thyroid | ATC | Ras protein signal transduction | 172/6293 | 337/18723 | 2.25e-11 | 7.96e-10 | 172 |
GO:004828512 | Thyroid | ATC | organelle fission | 229/6293 | 488/18723 | 4.79e-10 | 1.29e-08 | 229 |
GO:0010821112 | Thyroid | ATC | regulation of mitochondrion organization | 82/6293 | 144/18723 | 7.15e-09 | 1.54e-07 | 82 |
GO:005105618 | Thyroid | ATC | regulation of small GTPase mediated signal transduction | 141/6293 | 302/18723 | 1.43e-06 | 1.77e-05 | 141 |
GO:000726619 | Thyroid | ATC | Rho protein signal transduction | 73/6293 | 137/18723 | 1.58e-06 | 1.93e-05 | 73 |
GO:004657818 | Thyroid | ATC | regulation of Ras protein signal transduction | 94/6293 | 189/18723 | 3.12e-06 | 3.55e-05 | 94 |
GO:001082216 | Thyroid | ATC | positive regulation of mitochondrion organization | 43/6293 | 74/18723 | 1.30e-05 | 1.25e-04 | 43 |
GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
GO:000963634 | Thyroid | ATC | response to toxic substance | 119/6293 | 262/18723 | 4.30e-05 | 3.48e-04 | 119 |
GO:00901413 | Thyroid | ATC | positive regulation of mitochondrial fission | 14/6293 | 21/18723 | 1.99e-03 | 9.54e-03 | 14 |
GO:003502314 | Thyroid | ATC | regulation of Rho protein signal transduction | 42/6293 | 86/18723 | 2.43e-03 | 1.13e-02 | 42 |
GO:00901401 | Thyroid | ATC | regulation of mitochondrial fission | 19/6293 | 32/18723 | 2.46e-03 | 1.14e-02 | 19 |
GO:004354715 | Thyroid | ATC | positive regulation of GTPase activity | 106/6293 | 255/18723 | 4.58e-03 | 1.89e-02 | 106 |
GO:009875433 | Thyroid | ATC | detoxification | 66/6293 | 152/18723 | 7.23e-03 | 2.85e-02 | 66 |
GO:00002663 | Thyroid | ATC | mitochondrial fission | 22/6293 | 42/18723 | 9.23e-03 | 3.44e-02 | 22 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RALBP1 | SNV | Missense_Mutation | novel | c.1744N>A | p.Glu582Lys | p.E582K | Q15311 | protein_coding | tolerated(0.05) | benign(0.111) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
RALBP1 | SNV | Missense_Mutation | | c.1316N>C | p.Leu439Pro | p.L439P | Q15311 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
RALBP1 | SNV | Missense_Mutation | | c.1278A>C | p.Glu426Asp | p.E426D | Q15311 | protein_coding | tolerated(0.09) | benign(0.365) | TCGA-B6-A1KC-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RALBP1 | insertion | Nonsense_Mutation | novel | c.360_361insTCATTCCATTAGCCCTCTATGTAGAGCCTTTCAGGTGT | p.Lys121SerfsTer4 | p.K121Sfs*4 | Q15311 | protein_coding | | | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RALBP1 | SNV | Missense_Mutation | rs780034442 | c.47N>A | p.Arg16His | p.R16H | Q15311 | protein_coding | tolerated_low_confidence(0.16) | benign(0.011) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RALBP1 | SNV | Missense_Mutation | novel | c.1348N>C | p.Glu450Gln | p.E450Q | Q15311 | protein_coding | tolerated(0.16) | benign(0.035) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
RALBP1 | SNV | Missense_Mutation | novel | c.956N>A | p.Ser319Tyr | p.S319Y | Q15311 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-C5-A8ZZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | Cisplatin | SD |
RALBP1 | SNV | Missense_Mutation | | c.1825N>A | p.Glu609Lys | p.E609K | Q15311 | protein_coding | tolerated_low_confidence(0.25) | benign(0.026) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
RALBP1 | SNV | Missense_Mutation | novel | c.742N>C | p.Asp248His | p.D248H | Q15311 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-MA-AA3Z-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RALBP1 | SNV | Missense_Mutation | | c.892N>A | p.Glu298Lys | p.E298K | Q15311 | protein_coding | tolerated(0.2) | probably_damaging(0.998) | TCGA-Q1-A5R2-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PR |